ALLMedicine™ Acute Myeloid Leukemia Center

Dec 2nd, 2022 - Considerable progress has been made in the past several years in the scientific understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement of a conventional remission, evaluated cytomorphologically via small bone mar...

Dec 2nd, 2022 - Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis.|2022|Shimony S,Rozental A,Bewersdorf JP,Goldberg AD,Stein EM,|

Dec 1st, 2022 - The prognosis of pediatric acute myeloid leukemia (AML) has improved via stratification therapy. However, relapse or death occurs in 30%-40% of cases. Novel genetic factors for pediatric AML need to be elucidated to improve prognosis. We detected ...

Dec 1st, 2022 - Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. ...

Nov 30th, 2022 - Myelodysplasic Syndromes (MDS) are diseases occurring mainly in the elderly population. Although hematopoietic stem cell transplantation is the only hope for cure, a majority of the patients suffering from MDS are too old or frail for intensive tr...

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety and tolerability and recommended phase 2 dose (RP2D) of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with either ivosidenib (Arm A) or enasidenib (Arm B) for patients with acute...

Oct 14th, 2022 - Germline mutations in RUNX1 are responsible for familial platelet disorder with associated myeloid malignancies (FPDMM, or simply FPD), an autosomal dominant disease characterized by defective megakaryocytic development, low platelet counts, prolo...

Oct 14th, 2022 - This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloi...

Oct 14th, 2022 - Participants considered an adult according to local regulations at the time of signing informed consent may participate in this study. Participants will be randomized in a 2:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will ent...

Oct 14th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

Dec 2nd, 2022 - The FDA approved the IDH1 inhibitor olutasidenib (Rezlidhia) for relapsed or refractory acute myeloid leukemia (AML). The approved indication stipulates use of olutasidenib in relapsed/refractory AML associated with an IDH1 mutation. The FDA also ...

Dec 2nd, 2022 - The US Food and Drug Administration (FDA) has approved olutasidenib (Rezlidhia) for use in certain patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). Specifically, the drug is approved for use in patients who have R/R AML wit...

Dec 2nd, 2022 - Neurologic manifestations such as headache, neuropathy, seizures, and cell infiltration are common in pediatric patients with acute leukemia and are associated with a higher mortality rate, according to a retrospective, analytic, longitudinal stud...

Nov 21st, 2022 - The fields of diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) are quickly expanding to accommodate novel therapies such as polatuzumab vedotin-piiq (Polivy) plus R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vi...

Nov 21st, 2022 - The first patient in the chronic lymphocytic leukemia (CLL) cohort has been dosed in the phase 1 COVALENT-101 trial (NCT05153330), which is evaluating the first-in-class covalent menin inhibitor BMF-219, in patients with relapsed/refractory acute ...